Modality
mRNA
MOA
PLK4i
Target
GIP-R
Pathway
Amyloid
Thymoma
Development Pipeline
Preclinical
May 2021
→ Mar 2025
PreclinicalCurrent
NCT05509436
708 pts·Thymoma
2021-05→2025-03·Terminated
708 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-03-061.1y agoInterim· Thymoma
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
Preclinical
Termina…
Catalysts
Interim
2025-03-06 · 1.1y ago
Thymoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05509436 | Preclinical | Thymoma | Terminated | 708 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| TNG-8610 | Tango Ther | NDA/BLA | GIP-R | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D |